Jun activation domain-binding protein 1 negatively regulate p27 kip1 in non-Hodgkin's lymphomas

Cancer Biology and Therapy

Volumn 7, Issue 3, 2008, Pages 460-467

  Wang, Yuchan ^a   Fei, Min ^b   Cheng, Chun ^a   Zhang, Dongmei ^a   Lu, Jianxin ^a   He, Song ^a   Zhao, Yueming ^a   Wang, You ^a   Shen, Aiguo ^a  

^a NANTONG UNIVERSITY   (China)

^b SOOCHOW UNIVERSITY   (China)

Author keywords

Cell cycle; Clinicopathologic variables; Immunohistochemistry; Jab1; Non hodgkin's lymphomas; p27kip1; Phosphorylation; Survival analysis

Indexed keywords

BINDING PROTEIN; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE INHIBITOR 1B; JUN ACTIVATION DOMAIN BINDING PROTEIN 1; SERINE; THREONINE;

ADULT; ARTICLE; CANCER SURVIVAL; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CELL FRACTIONATION; CLINICAL FEATURE; CONTROLLED STUDY; CORRELATION ANALYSIS; CULTURE MEDIUM; DISSOCIATION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; LEUKEMIA CELL LINE; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; NONHODGKIN LYMPHOMA; OVERALL SURVIVAL; PROGNOSIS; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; PROTEIN TRANSPORT; TUMOR GROWTH; WESTERN BLOTTING;

EID: 45349089774     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.7.3.5456     Document Type: Article

References (35)

1. Claret FX, Hibi M, Dhut S, Toda T, Karin M. A new group of conserved coactivators that increase the specificity of AP-1 transcription factors. Nature 1996; 383:453-7.
2. Chamovitz DA, Segal D. JAB1/CSN5 and the COP9 signalosome. A complex situation. EMBO Rep 2001; 2:96-101.
3. Schwechheimer C, Deng XW. COP9 signalosome revisited: a novel mediator of protein degradation. Trends Cell Biol 2001; 11:420-6.
4. Tomoda K, Kubota Y, Arata Y, Mori S, Maeda M, Tanaka T, et al. The cytoplasmic shuttling and subsequent degradation of p27Kip1 mediated by Jab1/CSN5 and the COP9 signalosome complex. J Biol Chem 2002; 277:2302-10.
5. Lee EW, Oh W, Song J. Jab1 as a mediator of nuclear export and cytoplasmic degradation of p53. Mol Cells 2006; 22:133-40.
6. Polyak K, Lee MH, Erdjument Bromage H, Koff A, Roberts JM, Tempst P, et al. Cloning of p27Kip1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. Cell 1994; 78:59-66.
7. 1-phase progression. Genes Dev 1999; 13:1501-12.
8. Pagano M, Tam SW, Theodoras AM, Beer Romero P, Del Sal G, Chau V, et al. Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. Science 1995; 269:682-5.
9. Sheaff RJ, Groudine M, Gordon M, Roberts JM, Clurman BE. Cyclin E-CDK2 is a regulator of p27Kip1. Genes Dev 1997; 11:1464-78.
10. Vlach J, Hennecke S, Amati B. Phosphorylation-dependent degradation of the cyclin-dependent kinase inhibitor p27. EMBO J 1997; 16:5334-44.
11. Montagnoli A, Fiore F, Eytan E, Carrano AC, Draetta GF, Hershko A, et al. Ubiquitination of p27 is regulated by Cdk-dependent phosphorylation and trimeric complex formation. Genes Dev 1999; 13:1181-9.
12. Sui L, Do9-p/ng Y, Ohno M, Watanabe Y, Sugimoto K, Tai Y, et al. Jab1 expression is associated with inverse expression of p27(kip1) and poor prognosis in epithelial ovarian tumors. Clin Cancer Res 2003; 7:4130-5.
13. Kouvaraki MA, Rassidakis GZ, Tian L, Kumar R, Kittas C, Claret FX. Jun activation domain-binding protein 1 expression in breast cancer inversely correlates with the cell cycle inhibitor p27(Kip1). Cancer Res 2003; 63:2977-81.
14. Kouvaraki MA, Korapati AL, Rassidakis GZ, Tian L, Zhang Q, Chiao P, et al. Potential Role of Jun Activation Domain-Binding Protein 1 as a Negative Regulator of p27kip1 in Pancreatic Adenocarcinoma. Cancer Res 2006; 66:8581-9.
15. Shintani S, Li C, Mihara M, Hino S, Nakashiro K, Hamakawa H. Skp2 and Jab1 expression are associated with inverse expression of p27(KIP1) and poor prognosis in oral squamous cell carcinomas. Oncology 2003; 65:355-62.
16. Rassidakis GZ, Claret FX, Lai R, Zhang Q, Sarris AH, McDonnell TJ, et al. Expression of p27(Kip1) and c-Jun activation binding protein 1 are inversely correlated in systemic anaplastic large cell lymphoma. Clin Cancer Res 2003; 9:1121-8.
17. Chiarle R, Budel LM, Skolnik J, Frizzera G, Chilosi M, Corato A, et al. Increased proteasome degradation of cyclin-dependent kinase inhibitor p27 is associated with a decreased overall survival in mantle cell lymphoma. Blood 2000; 95:619-26.
18. Lenferink AE, Busse D, Flanagan WM, Yakes FM, Arteaga CL. ErbB2/neu kinase modulates cellular p27(Kip1) and cyclin D1 through multiple signaling pathways. Cancer Res 2001; 61:6583-91.
19. Erlanson M, Portin C, Linderholm B, Lindh J, Roos G, Landberg G. Expression of cyclin E and the cyclin-dependent kinase inhibitor p27 in malignant lymphomas-prognostic implications. Blood 1998; 92:770-7.
20. Sanchez Beato M, Saez AI, Martinez Montero JC, Sol Mateo M, Sanchez Verde L, Villuendas R, et al. Cyclin-dependent kinase inhibitor p27KIP1 in lymphoid tissue: p27KIP1 expression is inversely proportional to the proliferative index. Am J Pathol 1997; 151:151-60.
21. Chamovitz DA, Segal D. JAB1/CSN5 and the COP9 signalosome. A complex situation. EMBO Rep 2001; 2:96-101.
22. Tomoda K, Kubota Y, Kato J. Degradation of the cyclin-dependent-kinase inhibitor p27Kip1 is instigated by Jab1. Nature 1999; 398:160-5.
23. 1 arrest. Nat Med 2002; 8:1153-60.
24. Viglietto G, Motti ML, Bruni P, Melillo RM, D'Alessio A, Califano D, et al. Cytoplasmic relocalization and inhibition of the cyclin-dependent kinase inhibitor p27kip1 by PKB/Akt-mediated phosphorylation in breast cancer. Nat Med 2002; 8:1136-44.
25. Shin I, Yakes MF, Rojo F, Shin NY, Bakin AV, Baselga J, et al. PKB/Akt mediates cell cycle progression by phosphorylation of p27kip1 at threonine 157 and modulation of its cellular localization. Nat Med 2002; 8:1145-52.
26. Boehm M, Yoshimoto T, Crook MF, Nallamshetty S, True A, Nabel GJ, et al. A growth factor-dependent nuclear kinase phosphorylates p27(Kip1) and regulates cell cycle progression. EMBO J 2002; 21:3390-401.
27. Rodier G, Montagnoli A, Marcotullio LD, Coulombe P, Draetta GF, Pagano M, et al. p27 cytoplasmic localization is regulated by phosphorylation on Ser10 and is not a prerequisite for its proteolysis. EMBO J 2001; 20:6672-82.
28. Korbonits M, Chahal HS, Kaltsas G, Jordan S, Urmanova Y, Khalimova Z, et al. Expression of phosphorylated p27(Kip1) protein and Jun activation domain-binding protein 1 in human pituitary tumors. J Clin Endocrinol Metab 2002; 87:2635-43.
29. Esteva FJ, Sahin AA, Rassidakis GZ, Yuan LX, Smith TL, Yang Y, et al. Jun activation domain binding protein 1 expression is associated with low p27(Kip1) levels in node-negative breast cancer. Clin Cancer Res 2003; 9:5652-9.
30. Fukumoto A, Ikeda N, Sho M, Tomoda K, Kanehiro H, Hisanaga M, et al. Prognostic significance of localized p27Kip1 and potential role of Jab1/CSN5 in pancreatic cancer. Oncol Rep 2004; 11:277-84.
31. Zhang W, Bergamaschi D, Jin B, Lu X. Posttranslational modifications of p27kip1 determine its binding specificity to different cyclins and cyclin-dependent kinases in vivo. Blood 2005; 105:3691-8.
32. 0/1 phase arrest in the HepG2 cell line. Biochem Biophys Res Commun 2006; 347:601-7.
33. 1 and prevents nuclear re-entry. J Biol Chem 2005; 280:6055-63.
34. Quintanilla Martinez L, Davies Hill T, Fend F, Calzada Wack J, Sorbara L, Campo E, et al. Sequestration of p27Kip1 protein by cyclin D1 in typical and blastic variants of mantle cell lymphoma (MCL): implications for pathogenesis. Blood 2003; 101:3181-7.
35. 1 cyclin-dependent kinases. Genes Dev 1995; 9:1149-63.